Sign in
KPTI Stock Price, Chart, Stats & News
Karyopharm Therapeutics Inc.
Save
Karyopharm Therapeutics Inc. (KPTI) does not currently pay a dividend.
221.42M
Market cap
–
Current P/E
–
Forward P/E
KPTI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.93% |
Operating margin | -62.10% |
Pretax margin | -134.18% |
Net margin | -134.21% |
Effective tax rate | -0.02% |
ROA | -180.82% |
ROE | 77.87% |
D/E | -0.80x |
Interest coverage ratio | -1.98x |
KPTI valuation
P/E | – |
P/S | 0.32x |
P/B | -0.34x |
P/CF | -1.31x |
P/FCF | -0.62x |
P/OCF | -1.31x |
PEG | 0.04x |
EV multiple | 1.61x |
About
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1.
Similar securities
Based on sector and market capitalization
Report issue